CAJ | 학술논문

目的：探讨舒血宁联合磷酸肌酸钠对急性重度一氧化碳中毒（acute severe carbon monoxide poisoning， ASCOP）患者缺血修饰白蛋白水平（Ischemia modified albumin， IMA）的影响及其疗效比较。方法：选择ASCOP患者66例随机分为常规组及治疗组，入选者治疗前、治疗后6 h、3 d分别抽取静脉血检测心肌酶、cTnI、IMA。结果：治疗前两组IMA显著降低，而心肌酶、cTnI无明显改变。治疗后6 h，治疗组IMA升高较常规组明显（P＜0．05）。两组心肌酶、cTnI逐渐升高，组间比较差异无统计学意义（P＞0．05）。治疗后3 d，常规组cTnI较治疗组升高明显（P＜0．05）。两组心肌酶、IMA恢复正常水平，组间比较差异无统计学意义。治疗后3 d cTnI与治疗后6 h比较明显好转。结论：ASCOP患者早期给予舒血宁联合磷酸肌酸钠治疗，可改善中毒性心肌损伤，具有心肌保护作用，IMA水平可作为心肌缺血及药物治疗的评价指标。
목적：탐토서혈저연합린산기산납대급성중도일양화탄중독（acute severe carbon monoxide poisoning， ASCOP）환자결혈수식백단백수평（Ischemia modified albumin， IMA）적영향급기료효비교。방법：선택ASCOP환자66례수궤분위상규조급치료조，입선자치료전、치료후6 h、3 d분별추취정맥혈검측심기매、cTnI、IMA。결과：치료전량조IMA현저강저，이심기매、cTnI무명현개변。치료후6 h，치료조IMA승고교상규조명현（P＜0．05）。량조심기매、cTnI축점승고，조간비교차이무통계학의의（P＞0．05）。치료후3 d，상규조cTnI교치료조승고명현（P＜0．05）。량조심기매、IMA회복정상수평，조간비교차이무통계학의의。치료후3 d cTnI여치료후6 h비교명현호전。결론：ASCOP환자조기급여서혈저연합린산기산납치료，가개선중독성심기손상，구유심기보호작용，IMA수평가작위심기결혈급약물치료적평개지표。
Objective Study of Shuxuening combined with sodium phosphocreatine on acute severe carbon monoxide poisoning with ischemia modified albumin level and its curative effect in patients. Methods 66 cases of ASCOP patients were randomly divided into routine group and treatment group, all patients were detected for myocardial enzymes, cTnI, IMA before treatment, after treatment 6 h and 3 d. Results IMA was significantly decreased before treatment, while no significant changes occurred in myocardial enzymes and cTnIn levels. After treatment for 6 h, IMA in treatment group was higher than conventional group (P < 0.05). Myocardial enzymes and cTnI gradually increased, the two groups had no difference (P>0.05). After treatment for 3d, cTnI level of normal group increased obviously compare with the treatment group (P>0.05). Myocardial enzymes, IMA restored to the normal level (P>0.05). The level of cTnI after treatment for 3 d improved compare with 6 h. Conclusion Treatment of early ASCOP patients by Shuxuening combined with sodium phosphocreatine significantly improve the recovery of myocardial injury poisoning. The level of IMA can be used as evaluation index of myocardial ischemia and drug treatment.